Dr. Kotra is an academic entrepreneur with expertise in drug discovery and development. Kotra group specializes in the areas of medicinal chemistry, preclinical and clinical development of small molecule and natural product-based drugs.
Kotra research group has contributed to a number of research programs in the areas of infectious, metabolic and neurodegenerative diseases, cancer, thrombocytopenia among others. Dr. Kotra is a recipient of several awards including the Premier’s Research Excellence Award from the Province of Ontario (Canada), Rx&D Health Research Foundation Research Career award, GlaxoSmithKline/Canadian Society for Pharmaceutical Sciences Young Investigator Award.
Dr. Kotra leads an international consortium with India for the development of novel chemical classes of drugs targeting malaria—a consortium of public and private organizations in Canada and India. Dr. Kotra is a co-founder of WinSanTor Inc., San Diego, California, USA (drugs targeting diabetic neuropathy, 2012-present), CIDAVA Innovations—an India-Canada joint venture (antimalarials, 2013-17), CannScience Innovations, Inc., Toronto, Canada (now Scientus Pharma, Inc.; novel cannabinoid products for medical uses, 2014-2019).
Speaking at Medical Cannabis Treatment: Separating Myth from Fact